Skip to content
Therapy But Better – Lifestyle
Author:
Eisai Inc.
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
November 18, 2026
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
November 16, 2026
Eisai and Linus Health Launch New Online Resource to Help Adults Explore Their Brain Health
November 12, 2026
Eisai to Present New Five-Year Lecanemab Data and Real-World Alzheimer’s Disease Research at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 29, 2026
Survey Findings Presented at ESMO Congress 2026 Highlight How Chemotherapy Can Impact the Daily Lives of Patients Living with Endometrial Cancer
October 26, 2026
Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026
October 15, 2026
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
August 24, 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 14, 2026
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 14, 2026
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
July 13, 2026
1
2
Next Page
→